Vor Biopharma Inc. (VOR): Price and Financial Metrics


Vor Biopharma Inc. (VOR): $4.22

0.33 (+8.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VOR to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VOR Stock Price Chart Interactive Chart >

Price chart for VOR

VOR Price/Volume Stats

Current price $4.22 52-week high $23.53
Prev. close $3.89 52-week low $3.83
Day low $3.88 Volume 29,900
Day high $4.25 Avg. volume 95,793
50-day MA $5.58 Dividend yield N/A
200-day MA $10.77 Market Cap 158.30M

Vor Biopharma Inc. (VOR) Company Bio


Vor BioPharma Inc. operates as a clinical stage cell therapy company. The Company specializes in developing novel therapies for treating cancer. Vor BioPharma focuses on discovering technologies that can enable selective targeting of cancer cells without impacting normal cells. Vor BioPharma serves customers in the United States.


VOR Latest News Stream


Event/Time News Detail
Loading, please wait...

VOR Latest Social Stream


Loading social stream, please wait...

View Full VOR Social Stream

Latest VOR News From Around the Web

Below are the latest news stories about Vor Biopharma Inc that investors may wish to consider to help them evaluate VOR as an investment opportunity.

Vor Biopharma Inc.’s (VOR) Stock Is Harder To Predict Than You Think

Vor Biopharma Inc. (NASDAQ:VOR) price on Friday, February 11, fall -7.03% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.60. A look at the stock’s price movement, the close in the last trading session was $9.25, moving within a range at $8.35 and $9.65. Turning to its … Vor Biopharma Inc.’s (VOR) Stock Is Harder To Predict Than You Think Read More »

Stocks Register | February 12, 2022

Vor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference.

GlobeNewswire | February 11, 2022

Vor to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that members of its senior management team will be participating in two upcoming virtual investor conferences: H.C. Wainwright BioConnect 2022 Virtual Conference Presentation Date: Monday, January 10, 2022Time: Pre-recorded on-demand presentation available beginning at 7:00 AM ET 2022 B Riley Virtual Oncology ConferenceFireside Chat Live Webcast D

Yahoo | January 4, 2022

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $40.44

Vor Biopharma Inc. (NYSE:VOR) has earned an average rating of Buy from the ten brokerages that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12-month price objective []

Transcript Daily | December 19, 2021

Vor Biopharma (NYSE:VOR) Downgraded to Hold at Zacks Investment Research

Vor Biopharma (NYSE:VOR) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Saturday, Zacks.com reports. According to Zacks, Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. []

Dakota Financial News | December 18, 2021

Read More 'VOR' Stories Here

VOR Price Returns

1-mo -26.35%
3-mo -53.27%
6-mo -63.43%
1-year -80.00%
3-year N/A
5-year N/A
YTD -63.68%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5486 seconds.